Instadose Operating Income vs Net Debt Analysis
| INSD Stock | USD 0 0.00 0.00% |
Instadose Pharma financial indicator trend analysis is infinitely more than just investigating Instadose Pharma Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Instadose Pharma Corp is a good investment. Please check the relationship between Instadose Pharma Operating Income and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Instadose Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Operating Income vs Net Debt
Operating Income vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Instadose Pharma Corp Operating Income account and Net Debt. At this time, the significance of the direction appears to have strong relationship.
The correlation between Instadose Pharma's Operating Income and Net Debt is 0.68. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Net Debt in the same time period over historical financial statements of Instadose Pharma Corp, assuming nothing else is changed. The correlation between historical values of Instadose Pharma's Operating Income and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Instadose Pharma Corp are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Operating Income i.e., Instadose Pharma's Operating Income and Net Debt go up and down completely randomly.
Correlation Coefficient | 0.68 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Operating Income
Operating Income is the amount of profit realized from Instadose Pharma Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Instadose Pharma Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Instadose Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Instadose Pharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Instadose Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At present, Instadose Pharma's Enterprise Value is projected to increase significantly based on the last few years of reporting.
Instadose Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Instadose Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Instadose Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Current Liabilities | 33.5K | 56.7K | 82.4K | 162.3K | 186.6K | 196.0K | |
| Total Stockholder Equity | (33.4K) | (56.7K) | (82.4K) | (162.3K) | (146.1K) | (138.8K) | |
| Net Tangible Assets | (33.4K) | (56.7K) | (82.4K) | (162.3K) | (146.1K) | (138.8K) | |
| Retained Earnings | (57.4K) | (80.7K) | (106.4K) | (568.4K) | (511.5K) | (486.0K) | |
| Accounts Payable | 797.0 | 1.0K | 82.4K | 77.6K | 89.2K | 93.7K | |
| Total Liab | 33.5K | 56.7K | 82.4K | 162.3K | 186.6K | 196.0K | |
| Net Invested Capital | (33.4K) | (56.7K) | (82.4K) | (162.3K) | (146.1K) | (138.8K) | |
| Net Working Capital | (33.4K) | (56.7K) | (82.4K) | (162.3K) | (146.1K) | (138.8K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Instadose Pharma Corp is a strong investment it is important to analyze Instadose Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Instadose Pharma's future performance. For an informed investment choice regarding Instadose Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Instadose Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instadose Pharma. If investors know Instadose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Instadose Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (694.06) |
The market value of Instadose Pharma Corp is measured differently than its book value, which is the value of Instadose that is recorded on the company's balance sheet. Investors also form their own opinion of Instadose Pharma's value that differs from its market value or its book value, called intrinsic value, which is Instadose Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Instadose Pharma's market value can be influenced by many factors that don't directly affect Instadose Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Instadose Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instadose Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instadose Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.